1. Home
  2. TBPH vs CYH Comparison

TBPH vs CYH Comparison

Compare TBPH & CYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • CYH
  • Stock Information
  • Founded
  • TBPH 2013
  • CYH 1985
  • Country
  • TBPH United States
  • CYH United States
  • Employees
  • TBPH N/A
  • CYH N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • CYH Hospital/Nursing Management
  • Sector
  • TBPH Health Care
  • CYH Health Care
  • Exchange
  • TBPH Nasdaq
  • CYH Nasdaq
  • Market Cap
  • TBPH 536.5M
  • CYH 482.7M
  • IPO Year
  • TBPH N/A
  • CYH 1991
  • Fundamental
  • Price
  • TBPH $11.15
  • CYH $3.41
  • Analyst Decision
  • TBPH Strong Buy
  • CYH Hold
  • Analyst Count
  • TBPH 5
  • CYH 8
  • Target Price
  • TBPH $16.60
  • CYH $4.27
  • AVG Volume (30 Days)
  • TBPH 245.1K
  • CYH 2.5M
  • Earning Date
  • TBPH 08-04-2025
  • CYH 07-23-2025
  • Dividend Yield
  • TBPH N/A
  • CYH N/A
  • EPS Growth
  • TBPH N/A
  • CYH N/A
  • EPS
  • TBPH N/A
  • CYH N/A
  • Revenue
  • TBPH $65,266,000.00
  • CYH $12,653,000,000.00
  • Revenue This Year
  • TBPH $43.18
  • CYH N/A
  • Revenue Next Year
  • TBPH N/A
  • CYH $3.49
  • P/E Ratio
  • TBPH N/A
  • CYH N/A
  • Revenue Growth
  • TBPH 6.11
  • CYH 1.05
  • 52 Week Low
  • TBPH $7.44
  • CYH $2.24
  • 52 Week High
  • TBPH $11.82
  • CYH $6.29
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 62.38
  • CYH 51.68
  • Support Level
  • TBPH $10.87
  • CYH $3.31
  • Resistance Level
  • TBPH $11.44
  • CYH $3.62
  • Average True Range (ATR)
  • TBPH 0.29
  • CYH 0.16
  • MACD
  • TBPH -0.00
  • CYH 0.01
  • Stochastic Oscillator
  • TBPH 71.92
  • CYH 70.45

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CYH Community Health Systems Inc.

Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.

Share on Social Networks: